Blog

Report: Price for blindness gene therapy Luxturna is ‘four times too high’ at $850000 – Genetic Literacy Project


Genetic Literacy Project

Report: Price for blindness gene therapy Luxturna is 'four times too high' at $850000
Genetic Literacy Project
The report from the Institute for Clinical and Economic Review focused on the medicine Luxturna, the first-of-its-kind gene therapy approved for the U.S. market and the most expensive medicine by list price. It is the latest flashpoint in the debate
At $850000, price for new childhood blindness gene therapy four times too high, analysis saysPharmacy Today, American Pharmacists Association, pharmacist.com


6 amazing medical advancements to expect in 2018CNBC
Spark Therapeutics: Challenges Posed By SuccessSeeking Alpha

all 4 news articles »

2018-01-17 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.